Physician profile
Lauren Hare
NPI 1063055432
$3,288.68
in general payments reported to CMS, 2019-2025
44 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $784 · 2024: $1,347 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,208.69 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $260.82 | 2023-2025 | |
| Janssen Biotech, INC. | $201.46 | 2024-2025 | Tecvayli, Talvey |
| Daiichi Sankyo INC. | $191.79 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals Lp | $179.11 | 2023-2025 | Calquence |
| Glaxosmithkline, LLC. | $172.14 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $167.55 | 2024 | Iclusig, Alunbrig, Fruzaqla |
| Merck Sharp & Dohme LLC | $163.47 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $138.53 | 2023-2025 | |
| Lilly USA, LLC | $137.18 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $137.13 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $133.29 | 2024-2025 | Opdivo, Krazati |
| Novartis Pharmaceuticals Corporation | $127.51 | 2024-2025 | |
| Gilead Sciences, INC. | $108.42 | 2023-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $107.64 | 2023-2024 | Krazati |
| Janssen Pharmaceuticals, INC | $89.35 | 2023-2024 | Xarelto |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $70.35 | 2023-2024 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $65.96 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $54.04 | 2023 | Imbruvica, Epkinly |
| Incyte Corporation | $53.44 | 2025 | Monjuvi, Zynyz |
| Emd Serono, INC. | $40.98 | 2024 | |
| Sumitomo Pharma America, INC. | $39.66 | 2024 | Orgovyx |
| Adc Therapeutics America, INC. | $39.29 | 2025 | |
| Genentech USA, INC. | $38.78 | 2023 | Venclexta, Columvi, Lunsumio |
| Amgen INC. | $35.42 | 2023 | Lumakras, Vectibix, Xgeva |
| Regeneron Healthcare Solutions, INC. | $35.27 | 2025 | Libtayo |
| Genmab U.S., INC. | $34.13 | 2024 | Epkinly |
| Jazz Pharmaceuticals INC. | $34.04 | 2024 | |
| Exelixis INC. | $33.93 | 2025 | Cabometyx |
| Pharmaessentia USA Corporation | $31.35 | 2024 | Besremi |
| Beone Medicines USA, INC. | $30.24 | 2025 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $29.57 | 2025 | Onivyde |
| Azurity Pharmaceuticals, INC. | $28.81 | 2025 | Danziten |
| Alexion Pharmaceuticals, INC. | $28.21 | 2024 | Ultomiris |
| Astellas Pharma US INC | $26.38 | 2025 | Padcev |
| Beigene USA, INC. | $25.46 | 2024 | Brukinsa |
| Seagen INC. | $25.13 | 2023 | Tukysa |
| Blueprint Medicines Corporation | $24.46 | 2024 | Ayvakit |
| Coherus Oncology, INC. | $24.38 | 2025 | Loqtorzi |
| Immunogen, INC. | $23.87 | 2023 | Elahere |
| Caris Mpi, INC. | $23.75 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $20.89 | 2024 | Rolvedon |
| Sobi, INC | $19.32 | 2024 | |
| Recordati_rare_diseases_inc. | $18.88 | 2024 | Sylvant |
| Alnylam Pharmaceuticals INC. | $17.30 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.